Prognostic and predictive value of a novel immuno-proliferative biomarker signature for targeted therapy efficacy in non-small cell lung cancer
{{output}}
Background: Non-small cell lung cancer (NSCLC) is a prevalent and lethal malignancy. Although targeted therapies have improved clinical outcomes for patients with driver gene mutations, significant variability in treatment effica... ...
